Abstract Title:

Potential chemotherapeutic effects of diosgenin, zoledronic acid and epigallocatechin-3-gallate on PE/CA-PJ15 oral squamous cancer cell line.

Abstract Source:

Arch Oral Biol. 2017 Oct ;82:141-146. Epub 2017 Jun 19. PMID: 28641180

Abstract Author(s):

Eduardo Pons-Fuster López, Qin-Tong Wang, Wei Wei, Pia López Jornet

Article Affiliation:

Eduardo Pons-Fuster López


OBJECTIVE: To study the potential chemotherapeutic effects of Diosgenin, zoledronic acid and Epigallocatechin-3-gallate on oral squamous cell cancer (OSCC).

MATERIALS AND METHODS: Cell viability, migration, apoptosis and cell cycle evaluation assays were performed in order to assess the effects of different doses of Diosgenin, zoledronic acid and Epigallocatechin-3-gallate on the PE/CA-PJ15 cell line.

RESULTS: Doses of 100μM of diosgenin or zoledronic acid reduced cell viability significantly after 72h (p<0.001), as well as increasing apoptosis (p<0.05 and p<0.01 respectively). All three agents reduced cell migration and altered the cell cycle, each at a different phase of the cycle.

CONCLUSION: while DG and ZA reduced cell viability, increased apoptosis, inhibited cell migration and modified the cell cycle in different ways, EGCG only modified the cell cycle and reduced cell migration. These agents present a potential chemotherapeutic effect on PE/CA-PJ15 OSSC cell line, which have to be further studied.

Print Options

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.